Clinical trial · Observational
Clinical Characteristics of Infantile Hemangioma
Clinical Characteristics of Infantile Hemangioma: a Prospective Study
NCT03331744CI-TRIAL-00073263unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary purpose of this study is to identify the clinical characteristics of infantile hemangioma (IH) in our single center in China. The second objective of the study is to identify the clinical features of infantile hepatic hemangioma (IHH) and ulceration in patients with IHs.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hemangioma | Hemangioma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Location, size, phase of growth, morphologic subtypes, complication and outcome of IHs in patients.
- timeFrame
- 2 years
- description
- Clinical characteristics of infantile hemangioma. Phase of growth include proliferation, plateau and involution phase. Morphologic subtypes include localized, segmental, indeterminate and multifocal type.
Secondary outcomes (4)
- measure
- Demographic information of IH about patient gender, birth weight, race, gestational age, prenatal testing procedures, placental abnormalities, maternal complications during pregnancy, type of fertilization and delivery type are collected.
- timeFrame
- 2 years
- description
- Demographic characteristics in patients with IH.
- measure
- Demographic information of IHH about patient gender, birth weight, race, gestational age, prenatal testing procedures, placental abnormalities, maternal complications during pregnancy, type of fertilization and delivery type are collected.
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 6 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≤6 years old * Diagnose of IHs * Consent of both parents (or the person having parental authority in families) Exclusion Criteria: * Congenital hemangioma, kaposiform hemangioendothelioma, or other vascular anomalies * Age\>6 years * Hemangioma has been previous treated with corticosteroids, laser, cryotherapy, or only other treatments * Patients with an inability to participate or to follow the study treatment and assessment plan
References
Publications (5)
- DERIVEDLan YR, Zhang ZX, Yang LY, Yang M, Qiu T, Zhang KZ, Zhou JY, Gong X, Zhang XP, He CS, Peng Q, Hou F, Shan W, Bao PQ, Xia CC, Chen SY, Ji Y. Propranolol monotherapy versus propranolol plus prednisone for diffuse infantile hepatic haemangioma: a randomized clinical trial. World J Pediatr. 2026 Jun;22(6):655-663. doi: 10.1007/s12519-026-01070-1. Epub 2026 Jul 14. PMID 42449025
- DERIVEDZhang K, Qiu T, Zhou J, Gong X, Lan Y, Zhang Z, Ji Y. Comparison of Infantile Hemangiomas in Male and Female Infants: A Prospective Study. J Dermatol. 2025 Oct;52(10):1555-1560. doi: 10.1111/1346-8138.17885. Epub 2025 Jul 25. PMID 40715016
- DERIVEDZhou J, Zhang Z, Lan Y, Yang M, Qiu T, Yang K, Zhang X, Jiang X, Hou F, Shan W, Kong F, Hu F, Chen S, Ji Y. Long-Term Outcomes of Oral Propranolol for Facial Infantile Hemangioma. Plast Reconstr Surg. 2026 Jan 1;157(1):142-149. doi: 10.1097/PRS.0000000000012186. Epub 2025 May 6. PMID 40327835
- DERIVEDGong X, Yang M, Zhang Z, Qiu T, Zhou J, Shan W, Zhang X, Lan Y, Bao P, Zhou Z, Yang C, Zhang Y, Li T, Guo J, Guo J, Lu G, Kong F, Zhang Y, Chen S, Ji Y. Clinical characteristics and managements of congenital hepatic hemangioma: a cohort study of 211 cases. Hepatol Int. 2025 Jun;19(3):682-691. doi: 10.1007/s12072-024-10756-5. Epub 2024 Nov 29. PMID 39612031
- DERIVEDGong X, Qiu T, Feng L, Yang K, Dai S, Zhou J, Zhang X, Chen S, Ji Y. Maternal and Perinatal Risk Factors for Infantile Hemangioma: A Matched Case-Control Study with a Large Sample Size. Dermatol Ther (Heidelb). 2022 Jul;12(7):1659-1670. doi: 10.1007/s13555-022-00756-4. Epub 2022 Jun 25. PMID 35751738